Blood coagulation test reagent, method for producing blood coagulation test reagent, method for producing recombinant tissue factor, and recombinant tissue factor
The use of Gram-positive bacteria for producing recombinant tissue factor addresses the challenges of conventional blood coagulation test reagents by providing a cost-effective and active recombinant tissue factor for blood coagulation measurements, enhancing manufacturing efficiency and consistency.
Patent Information
- Application Number
- PCT/JP2024/018175
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-18
- Filing Date
- 2024-05-16
- Publication Date
- 2024-11-21
AI Technical Summary
Conventional blood coagulation test reagents using animal-derived tissue factor face issues such as contamination, lot-to-lot differences, high production costs, and complexity in manufacturing, particularly due to the use of animal cells and difficulty in forming disulfide bonds in E. coli expression systems.
Production of recombinant tissue factor using Gram-positive bacteria like Brevibacillus, Lactobacillus, and Bacillus, which facilitates a homogeneous and cost-effective manufacturing process with sufficient activity for blood coagulation measurements, involving gene introduction, selection, and culturing steps to express the extracellular domain of tissue factor.
This approach results in a recombinant tissue factor with high manufacturing cost and productivity merits, capable of activating blood coagulation factor VII, offering a standardized and efficient blood coagulation test reagent with improved lot consistency and reduced production costs.
Smart Images

Figure JPOXMLDOC01-APPB-T000001 
Figure JPOXMLDOC01-APPB-T000002 
Figure JPOXMLDOC01-APPB-T000003
Abstract
Description
Blood coagulation test reagent, method for producing blood coagulation test reagent, method for producing recombinant tissue factor, and recombinant tissue factor
[0001] The present invention relates to a blood coagulation test reagent, a method for producing a blood coagulation test reagent, a method for producing a recombinant tissue factor, and a recombinant tissue factor. This application claims priority to Japanese Patent Application No. 2023-082387, filed May 18, 2023, the contents of which are incorporated herein by reference.
[0002] Tissue factor (TF), long known as tissue thromboplastin, is a membrane protein present on the membrane of cells not facing the vascular endothelium. When tissue factor leaks out of blood vessels along with membrane components due to vascular injury or other reasons, it activates blood coagulation factor VII (hereinafter simply referred to as "factor VII") and blood coagulation factor X (hereinafter simply referred to as "factor X"), initiating the extrinsic blood coagulation reaction. Blood coagulation time measurement reagents containing tissue factor, calcium, and phospholipids are clinically used to measure the blood coagulation time (prothrombin time, abbreviated as PT time) of plasma samples using this blood coagulation reaction. The molecular structure of tissue factor is a single-pass transmembrane protein consisting of an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is involved in the blood coagulation reaction, and the intracellular domain is involved in intracellular signal transduction. Biologically derived tissue factor, such as bovine or rabbit cerebrum, has long been used as tissue factor for blood coagulation test reagents. Furthermore, methods for producing recombinant tissue factor (rTF) using genetic engineering techniques have been developed. Non-Patent Documents 1, 2, and 3 disclose the production of human tissue factor protein containing a transmembrane domain using Escherichia coli. In all of these documents, the tissue factor expressed in Escherichia coli is purified by immunoaffinity purification using an antibody against the tissue factor or its tag. Patent Documents 1 and 2 also express recombinant tissue factor containing a transmembrane domain using insect cells or yeast as a protein expression host. Non-Patent Document 4 discloses that the extracellular domain alone was expressed and secreted as a secretory protein using Chinese hamster ovary cells (CHO cells), and the activity of the recombinant tissue factor was measured. Non-Patent Document 5 discloses that, by expressing tissue factor on the cell membrane using CHO cells and measuring tissue factor binding activity, one pair of disulfide bonds out of two pairs of disulfide bonds present in the tissue factor molecule is important for the formation of the molecular structure.Furthermore, Non-Patent Document 6 discloses that a secretory single-chain bispecific antibody was expressed by genetic recombination technology using the gram-positive bacterium Brevibacillus.
[0003] Patent No. 5073270 Patent No. 4813603
[0004] Neuenschwander, PF, and 3 others, "Phosphatidylethanolamine Augments Factor Vila-Tissue Factor Activity: Enhancement of Sensitivity to Phosphatidylserine," Biochemistry, 1995, Vol. 34, No. 43, pp. 13988-13993; Pabrosky, LR, and 12 others, "Purification of Recombinant Human Tissue Factor," Biochemistry, 1989, Vol. 28, No. 20, pp. 8072-8077; Rezaie, AR, and 4 others, "Expression and Purification of a Soluble Tissue Factor Fusion Protein with an Epitope for an Unusual Calcium-Dependent Antibody," Protein Expression and Purification, 1992, Vol. 3, No. 6, p. 453-460; Ruf, W. et al., "Phospholipid-independent and -dependent Interactions Required for Tissue Factor Receptor and Cofactor Function," The Journal of Biological Chemistry, 1991, Vol. 266, No. 4, pp. 2158-2166; Rehemtulla, A. et al., "The Integrity of the Cysteine 186-Cysteine 209 Bond of the Second Disulfide Loop of Tissue Factor Is Required for Binding of Factor VII," The Journal of Biological Chemistry, 1991, Vol. 266, No. 16, pp. 10294-10299; Asano, R., et al., "Comprehensive study of domain rearrangements of single-chain bispecific antibodies to determine the best combination of configurations and microbial host cells," mAbs, 2018, Vol. 10, No. 6, pp. 854-863.
[0005] Conventionally, reagents for measuring blood clotting time have used tissue thromboplastin derived from various animal-derived tissues, such as rabbit brain, bovine brain, or human placenta, or tissue thromboplastin obtained by binding recombinant tissue factor (rTF) to phospholipids. However, biologically derived raw materials have many problems, such as contamination with pathogenic substances such as mad cow disease and individual differences between raw material lots. Therefore, there is a demand for uniform blood clotting test reagents that do not use biologically derived raw materials, and the World Health Organization (WHO) has recommended the standardization of tissue thromboplastin.
[0006] On the other hand, from a bioethical perspective and for the purpose of obtaining a certain production volume, the production of rTF as a recombinant protein is being considered, but there are issues such as limitations on the molecular form of the rTF to be expressed and the use of animal cell hosts, which has high production costs.
[0007] The techniques disclosed in Non-Patent Documents 1 to 3 all involve expressing rTF using Escherichia coli and purifying the rTF using antibodies against rTF or a tag bound to rTF. Therefore, these techniques have the drawback of being complicated and expensive to produce. Furthermore, since disulfide bonds within the rTF molecule contribute to its activity, an expression system using Escherichia coli, which has difficulty forming disulfide bonds, is not suitable for producing secreted rTF.
[0008] The technique disclosed in Non-Patent Document 4 expresses secretory rTF using CHO cells. This technique produces rTF by animal cell culture, which poses a problem of production costs.
[0009] The technology disclosed in Patent Document 1 expresses bovine rTF using insect cells. This technology uses crude raw materials containing impurities without purifying the protein, but requires a culture device dedicated to insect cells and has the problem of lot-to-lot variation.
[0010] The technology disclosed in Patent Document 2 expresses rTF fused with a His tag. This technology uses a special expression system that expresses rTF on yeast microvesicles, which poses a problem of production costs.
[0011] An object of the present invention is to provide a homogeneous recombinant tissue factor that has significant advantages in terms of production cost and productivity and has sufficient activity in blood coagulation measurements, a method for producing the same, and a blood coagulation test reagent using the tissue factor and a method for producing the same.
[0012] The present inventors discovered that the above-mentioned problems can be solved by producing recombinant tissue factor by genetic recombination techniques using Gram-positive bacteria, and thus completed the present invention.
[0013] [1] A blood coagulation test reagent comprising a recombinant tissue factor produced using Gram-positive bacteria. [2] The blood coagulation test reagent according to [1], wherein the Gram-positive bacteria is at least one bacterium selected from the group consisting of bacteria of the genus Brevibacillus, bacteria of the genus Lactobacillus, and bacteria of the genus Bacillus. [3] The blood coagulation test reagent according to [1] or [2], wherein the recombinant tissue factor has the ability to activate blood coagulation factor VII. [4] The blood coagulation test reagent according to any one of [1] to [3], wherein the recombinant tissue factor is the extracellular domain of tissue factor. [5] The blood coagulation test reagent according to any one of [1] to [4], further comprising phospholipids and calcium. [6] A method for producing the blood coagulation test reagent according to any one of [1] to [5], comprising a step of producing recombinant tissue factor using Gram-positive bacteria. [7] A method for producing a recombinant tissue factor, comprising at least step C of: step A: introducing a gene encoding a recombinant tissue factor into a Gram-positive bacterium; step B: selecting a Gram-positive bacterium expressing the recombinant tissue factor; and step C: culturing cells expressing the recombinant tissue factor to express the recombinant tissue factor in a culture medium. [8] The method for producing a recombinant tissue factor according to [7], wherein the Gram-positive bacterium is at least one bacterium selected from the group consisting of bacteria of the genus Brevibacillus, bacteria of the genus Lactobacillus, and bacteria of the genus Bacillus. [9] The method for producing a recombinant tissue factor according to [7] or [8], wherein the recombinant tissue factor has the ability to activate blood coagulation factor VII.
[10] The method for producing a recombinant tissue factor according to any one of [7] to [9], wherein the recombinant tissue factor is the extracellular domain of tissue factor.
[11] A recombinant tissue factor produced by the method for producing a recombinant tissue factor according to any one of [7] to
[10] .
[0014] According to the present invention, it is possible to provide a homogeneous recombinant tissue factor which has significant advantages in terms of production cost and productivity and has sufficient activity in blood coagulation measurement, a method for producing the same, and a blood coagulation test reagent using the tissue factor and a method for producing the same.
[0015] Figure 1 shows the results of Western blotting of the supernatant fraction (S) and the bacterial cell fraction (C) of Example 1. Figure 2 shows the results of SDS-PAGE of the purified recombinant tissue factor of Example 1. Figure 3 shows the results of Western blotting of the cell culture supernatant of Example 3. Figure 4 shows the results of SDS-PAGE of the purified recombinant tissue factor of Example 3.
[0016] Although the embodiments of the present invention will be described in detail below, the present invention is not limited to the embodiments described below, and various modifications are possible without departing from the gist of the present invention.
[0017] [Blood Coagulation Test Reagent and Method for Producing a Blood Coagulation Test Reagent] A blood coagulation test reagent according to one embodiment of the present invention is a blood coagulation test reagent containing recombinant tissue factor (rTF) produced using Gram-positive bacteria.
[0018] A method for producing (manufacturing) rTF using gram-positive bacteria will be described later as "Method for producing recombinant tissue factor."
[0019] The Gram-positive bacterium is preferably at least one bacterium selected from the group consisting of Brevibacillus, Lactobacillus, and Bacillus bacteria, which will be described in detail in the section "Method for Producing Recombinant Tissue Factor."
[0020] The rTF preferably has the ability to activate blood coagulation factor VII. Whether rTF has the ability to activate blood coagulation factor VII can be confirmed by a conventionally known method, but it is preferable to measure the activity using, for example, a Tissue Factor Activity Assay kit (manufactured by ABCAM, ab108906).
[0021] The rTF may be any rTF having a structure derived from a tissue factor having blood coagulation activity, such as a rTF derived from human, bovine, rabbit, rat, or mouse tissue factor. The amino acid sequence of the tissue factor protein can be found by referring to IDs registered on UniProt or the like, such as human (UniProt ID: P13726), bovine (UniProt ID: P30931), rabbit (UniProt ID: P24055), rat (UniProt ID: P42533), and mouse (UniProt ID: P20352).
[0022] In this embodiment, at least one rTF selected from human, bovine, and rabbit is preferred, at least one rTF selected from human and bovine is more preferred, and human-derived rTF is most preferred. Even more preferred is rTF that contains a structure derived from tissue factors of the above-mentioned various origins and has the ability to activate blood coagulation factor VII that TF originally has.
[0023] Human tissue factor (abbreviated as "hTF") is a protein consisting of 295 amino acid residues (SEQ ID NO: 1), in which the amino acid sequence from positions 1 to 32 constitutes a signal sequence, the amino acid sequence from positions 33 to 251 constitutes an extracellular domain, the amino acid sequence from positions 252 to 274 constitutes a transmembrane domain, and the amino acid sequence from positions 275 to 295 constitutes an intracellular domain. The rTF used in the blood coagulation test reagent of this embodiment may be either the full-length tissue factor protein or a partial fragment thereof, as long as it has blood coagulation activity, and the amino acid sequence may contain amino acid modifications such as additions, deletions, or substitutions. One example of this embodiment is the use of a combination of amino acid sequences or domain sequences of TFs of various origins.
[0024] The rTF is preferably the extracellular domain of tissue factor. For example, the hTF-derived rTF is preferably the extracellular domain corresponding to the amino acid sequence of amino acids 33 to 251 of hTF (SEQ ID NO: 1). The hTF-derived rTF may have a part or all of the amino acid sequence of the N-terminal side of the transmembrane domain corresponding to the amino acid sequence of amino acids 252 to 274 of hTF (SEQ ID NO: 1) added to the C-terminal side of the amino acid sequence of amino acids 33 to 251 of hTF (SEQ ID NO: 1).
[0025] The amino acid modification permitted in this embodiment may include any amino acid modification as long as the rTF has the above-mentioned ability to activate factor VII. The rTF can be obtained by producing rTF using a conventional genetic recombination technique and evaluating its activity.
[0026] For detection and purification, it is preferable to add an affinity tag to the N-terminus or C-terminus of rTF, including, but not limited to, a PA tag (GVAMPGAEDDVV; SEQ ID NO: 6), a FRAG tag (DYKDDDDK; SEQ ID NO: 7), a 6xHis tag (HHHHHH; SEQ ID NO: 8, also simply referred to as "His tag"), and an HA tag (YPYDVPDYA; SEQ ID NO: 9).
[0027] The blood coagulation test reagent of this embodiment preferably further contains phospholipids and calcium. These phospholipids and calcium may be those used in conventional blood coagulation test reagents.
[0028] The blood coagulation test reagent of this embodiment may contain rTF produced from a gram-positive bacterium, phospholipids, and calcium. When the blood coagulation test reagent is used to measure the clotting ability of factor II, factor VII, factor IX, or factor X, the blood coagulation test reagent preferably contains rTF, phospholipids, calcium, and factors I and V, or contains plasma deficient in any one of the coagulation factors instead of adding factors I and V. Furthermore, when the clotting ability of any one of factor II, factor V, factor VII, factor IX, or factor X is measured, the blood coagulation test reagent preferably contains plasma deficient in any one of the coagulation factors.
[0029] When measuring the coagulation ability of factors II, VII, and X in combination, a blood coagulation test reagent containing rTF, phospholipids, calcium, and factors I and V is preferred. The coagulation factor-deficient plasma may be mixed with the blood coagulation test reagent, or may be used separately from the blood coagulation test reagent in a so-called "two-reagent system." The coagulation factor-deficient plasma can be used in either case.
[0030] When the blood coagulation test reagent of this embodiment is used for measuring prothrombin time, the blood coagulation test reagent preferably contains rTF produced from a gram-positive bacterium, phospholipids, and calcium.
[0031] The blood coagulation test reagent of this embodiment is preferably produced by a production method including a step of producing recombinant tissue factor using Gram-positive bacteria. The step of producing recombinant tissue factor using Gram-positive bacteria is the same as the "method for producing recombinant tissue factor" described below.
[0032] The Gram-positive bacteria may be any bacteria that are Gram-positive by Gram staining, and examples thereof include bacteria of the genera Brevibacillus, Lactobacillus, and Bacillus.
[0033] The Brevibacillus bacterium is not particularly limited as long as it is a bacterium of the genus Brevibacillus that conforms to the classification system of the genus Brevibacillus (see Shida, O. et al., 1996, Proposal for two new genera, Brevibacillus gen. nov. and Aneurinibacillus gen. nov., Int. J. Syst. Bacteriol., 46: 939-946.), and examples thereof include the Brevibacillus bacteria listed in LPSN - List of Prokaryotic names with Standing in Nomenclature (URL: https: / / www.bacterio.net / ).
[0034] Specific examples of the Brevibacillus bacteria include Brevibacillus brevis, Brevibacillus agri, Brevibacillus aydinogluensis, Brevibacillus borstelensis, Brevibacillus centrosporus, Brevibacillus choshinensis, and Brevibacillus compostii. Brevibacillus composti, Brevibacillus dissolubilis, Brevibacillus fulminis, Brevibacillus formosus, Brevibacillus fortis, Brevibacillus fulvus, Brevibacillus gelatini, Brevibacillus ginsengisori, Brevibacillus Brevibacillus ginsengisoli, Brevibacillus halotolerans, Brevibacillus humidisoli, Brevibacillus invocatus, Brevibacillus laterosporus, Brevibacillus levickii, Brevibacillus limnophilus, Brevibacillus marinus marinus), Brevibacillus massiliensis, Brevibacillus migulae,Brevibacillus nitrificans, Brevibacillus panacifumi, Brevibacillus parabrevis, Brevibacillus porteri, Brevibacillus reuszeri, Brevibacillus schisleri, Brevibacillus sediminis Examples of suitable bacterium species include Brevibacillus sediminis, Brevibacillus thermoruber, Brevibacillus antibioticus, and Brevibacillus texasporus.
[0035] The Lactobacillus bacteria are not particularly limited as long as they conform to the Lactobacillus classification system (see Zheng, J. et al., 2020, A taxonomic note on the genus Lactobacillus: Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae, Int. J. Syst. Evol. Microbiol., 70: 2782-2858.), and examples thereof include the Lactobacillus bacteria listed in LPSN - List of Prokaryotic names with Standing in Nomenclature (URL: https: / / www.bacterio.net / ).
[0036] Specific examples of the Lactobacillus bacteria include Lactobacillus acetotolerans, Lactobacillus acidophilus, Lactobacillus amylolyticus, Lactobacillus amylovorus, Lactobacillus apis, Lactobacillus bombicola, and Lactobacillus collinii. colini), Lactobacillus crispatus, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus delbrueckii subsp. delbrueckii, Lactobacillus delbrueckii subsp. indicus, Lactobacillus delbrueckii subsp. jakobsenii Lactobacillus delbrueckii subsp. jakobsenii, Lactobacillus delbrueckii subsp. lactis, Lactobacillus delbrueckii subsp. sunkii, Lactobacillus equicursoris, Lactobacillus fornicalis, Lactobacillus gallinarum, Lactobacillus gasseri gasseri), Lactobacillus gigeriorum, Lactobacillus hamsteri,Lactobacillus helsingborgensis, Lactobacillus helveticus, Lactobacillus hominis, Lactobacillus iners, Lactobacillus intestinalis, Lactobacillus jensenii, Lactobacillus johnsonii johnsonii), Lactobacillus kalixensis, Lactobacillus kefiranofaciens subsp. kefiranofaciens, Lactobacillus kefiranofaciens subsp. kefirgranum, Lactobacillus kimbladii, Lactobacillus kitasatonis Lactobacillus kitasatonis, Lactobacillus kulabergensis, Lactobacillus melliventris, Lactobacillus mulieris, Lactobacillus panisapium, Lactobacillus pasteurii, Lactobacillus porci, Lactobacillus psittaci psittaci), Lactobacillus rodentium, Lactobacillus taiwanensis, Lactobacillus ultunensis,Examples of suitable bacterial strains include, but are not limited to, Lactobacillus xujianguonis, Lactobacillus mulieris, and Lactobacillus paragasseri.
[0037] The Bacillus bacterium is not particularly limited as long as it is a Bacillus bacterium that conforms to the Bacillus classification system (see Gupta, RS et al. 2020, Robust demarcation of 17 distinct Bacillus species clades, proposed as novel Bacillaceae genera, by phylogenomics and comparative genomic analyses: description of Robertmurraya kyonggiensis sp. nov. and proposal for an emended genus Bacillus limiting it only to the members of the Subtilis and Cereus clades of species, Int. J. Syst. Evol. Microbiol., 70: 5753-5798.) or a related bacterium, and examples thereof include the Bacillus bacterium listed in LPSN - List of Prokaryotic names with Standing in Nomenclature (URL: https: / / www.bacterio.net / ).
[0038] Specific examples of the Bacillus bacteria include Bacillus subtilis, Bacillus aerius, Bacillus aerophilus, Bacillus altitudinis, Bacillus amyloliquefaciens, Bacillus atrophaeus, Bacillus australimalis, and Bacillus cabriaresii. cabrialesii), Bacillus capparidis, Bacillus glycinifermentans, Bacillus gobiensis, Bacillus halotolerans, Bacillus haynesii, Bacillus licheniformis, Bacillus mojavensis, Bacillus nakamurai nakamurai), Bacillus paralicheniformis, Bacillus pumilus, Bacillus safensis, Bacillus siamensis, Bacillus sonorensis, Bacillus stratosphericus, Bacillus swezeyi, Bacillus tequilensis, Bacillus valismortis, Bacillus vallismortis), Bacillus velezensis, Bacillus xiamenensis,and bacteria of the Subtilis clade such as Bacillus zhangzhouensis, Bacillus cereus, Bacillus albus, Bacillus anthracis, Bacillus cytotoxicus, Bacillus fungorum, Bacillus luti, Bacillus manliponensis, Bacillus mobilis, Bacillus cereus ... mobilis, Bacillus mycoides, Bacillus nitratireducens, Bacillus pacificus, Bacillus paramycoides, Bacillus parathracis, Bacillus proteolyticus, Bacillus pseudomycoides, Bacillus thuringiensis, Bacillus Bacteria of the Cereus clade, such as Bacillus thuringiensis, Bacillus toyonensis, Bacillus tropicalis, and Bacillus wiedmannii, as well as bacteria of the Cereus clade, such as Bacillus megaterium, Bacillus abyssalis, Bacillus aryabhattai, Bacillus endophyticus, Bacillus filamentousus, Bacillus spp. ... filamentosus), Bacillus flexus, Bacillus koreensis, Bacillus paraflexus,and Bacillus taiwanensis, and other bacteria of the Megaterium clade (Priestia genus bacteria).
[0039] Examples of phospholipids that can be contained in the blood coagulation test reagent of this embodiment include phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylglycerol (PG), phosphatidic acid (PA), phosphatidylinositol (PI), lysophosphatidylcholine (LPC), sphingomyelin (SM), and cardiolipin, and a mixture of multiple phospholipids can also be used as a liposome.
[0040] The calcium that can be contained in the blood coagulation test reagent of this embodiment may be any calcium that can exist as calcium ions in a liquid, and examples of such water-soluble calcium compounds include calcium chloride, calcium lactate, calcium carbonate, calcium gluconate, calcium glucuronate, and calcium tartrate.
[0041] Furthermore, the blood coagulation test reagent in this embodiment may contain a buffer having an appropriate buffering effect, and examples thereof include Good's buffers such as HEPES, MOPS, MOPSO, PIPES, ACES, TAPSO, POPS, CHES, and CAPS, as well as buffers such as phosphate, citric acid, acetic acid, glycine, imidazole, and Tris.
[0042] [Method for Producing Recombinant Tissue Factor, and Recombinant Tissue Factor] The method for producing a recombinant tissue factor of this embodiment includes at least a culture step among the steps of introducing a gene encoding the recombinant tissue factor into Gram-positive bacteria (introduction step), selecting Gram-positive bacteria expressing the recombinant tissue factor (selection step), and culturing cells expressing the recombinant tissue factor to express the recombinant tissue factor in a culture medium (culture step).
[0043] The Gram-positive bacterium is preferably at least one bacterium selected from the group consisting of bacteria of the genus Brevibacillus, bacteria of the genus Lactobacillus, and bacteria of the genus Bacillus.
[0044] In the introduction step, the method for introducing the gene encoding rTF into Gram-positive bacteria such as Brevibacillus bacteria such as Brevibacillus choshinensis or Bacillus bacteria such as Bacillus megaterium is not particularly limited, and the Gram-positive bacteria may be transformed using a vector to which DNA encoding rTF is linked. It is preferable to add a DNA base sequence encoding an affinity tag to the DNA encoding rTF. This makes it easier to detect and purify the target protein using the affinity tag.
[0045] The expression system is preferably one that secretes the target protein extracellularly, which facilitates separation of cellular components from soluble components by centrifugation, making it easier to obtain a purified protein with reduced cellular contaminants.
[0046] For example, the pROXb3 vector can be used to transform Brevibacillus bacteria. More specifically, a Brevibacillus secretion expression system (manufactured by Higeta Soy Sauce Co., Ltd.) using Brevibacillus choshinensis can be used. Alternatively, a protein expression service using a Brevibacillus expression system can be used.
[0047] For example, transformation of Bacillus megaterium can be carried out using a Bacillus megaterium expression system (manufactured by Mobitec) that uses an E. coli / B. megaterium shuttle vector and B. megaterium protoplasts.
[0048] In the selection step, if the expression vector containing the target gene DNA sequence has an antibiotic resistance gene, the target bacterial cells can be selected by adding an antibiotic to the medium. In addition, if an auxotrophic mutant strain is used, the gene-transferred cells can be selected using a medium lacking the nutrient.
[0049] In the culturing step, the bacterial cells selected in the selection step are cultured in a medium to express the target rTF. The expression level of the rTF secreted into the culture medium can be confirmed by detecting it using an immunological detection method using an antibody that specifically binds to the rTF or the linked affinity tag. Various known methods such as ELISA, Western blotting, and immunoprecipitation can be used.
[0050] After the culturing step, a step of recovering and purifying the target rTF may be carried out. For example, the rTF can be recovered by centrifuging the culture medium to separate the cells and the culture supernatant, and then recovering the supernatant. For example, the rTF can be purified by purifying the recovered culture supernatant using an affinity column.
[0051] The rTF obtained by the method for producing rTF of this embodiment preferably has the ability to activate blood coagulation factor VII. Whether rTF has the ability to activate blood coagulation factor VII can be confirmed by a conventionally known method, but it is preferable to measure the activity using, for example, a Tissue Factor Activity Assay kit (manufactured by ABCAM, ab108906).
[0052] The rTF may be any rTF having a structure derived from a tissue factor having blood coagulation activity, such as a tissue factor derived from human, bovine, rabbit, rat, or mouse. The amino acid sequence of the tissue factor protein can be found by referring to IDs registered on Uniport or the like, and includes human (P13726), bovine (P30931), rabbit (P24055), rat (P42533), and mouse (P20352) tissue factors.
[0053] In this embodiment, at least one rTF selected from human, bovine, and rabbit is preferred, at least one rTF selected from human and bovine is more preferred, and human-derived rTF is most preferred. Even more preferred is rTF that contains a structure derived from tissue factors of the above-mentioned various origins and has the ability to activate blood coagulation factor VII that TF originally has.
[0054] Human tissue factor (abbreviated as "hTF") is a protein consisting of 295 amino acid residues (SEQ ID NO: 1), in which the amino acid sequence from 1 to 32 is the signal sequence, the amino acid sequence from 33 to 251 is the extracellular domain, the amino acid sequence from 252 to 274 is the transmembrane domain, and the amino acid sequence from 275 to 295 is the intracellular domain. The rTF of this embodiment may be either the full-length tissue factor protein or a partial fragment thereof, as long as it has blood coagulation activity, and may contain amino acid modifications such as additions, deletions, or substitutions in the amino acid sequence. One example of this embodiment is the use of a combination of amino acid sequences of TFs of various origins or the sequences of each domain.
[0055] The rTF of this embodiment is preferably the extracellular domain of tissue factor. For example, the hTF-derived rTF is preferably the extracellular domain corresponding to the amino acid sequence of amino acids 33 to 251 of hTF (SEQ ID NO: 1). The hTF-derived rTF may have part or all of the amino acid sequence of the N-terminal side of the transmembrane domain corresponding to the amino acid sequence of amino acids 252 to 274 of hTF (SEQ ID NO: 1) added to the C-terminal side of the amino acid sequence of amino acids 33 to 251 of hTF (SEQ ID NO: 1).
[0056] For detection and purification, the rTF of this embodiment preferably has an affinity tag attached to its N-terminus or C-terminus. Examples of the affinity tag include, but are not limited to, a PA tag (GVAMPGAEDDVV; SEQ ID NO: 6), a FRAG tag (DYKDDDDK; SEQ ID NO: 7), a 6xHis tag (HHHHHH; SEQ ID NO: 8, also referred to simply as "His tag"), and an HA tag (YPYDVPDYA; SEQ ID NO: 9).
[0057] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to the examples described below.
[0058] Example 1 Expression and Purification of Recombinant Tissue Factor Protein 1. Test Method Recombinant tissue factor protein was expressed and purified using Brevibacillus bacteria in the same manner as described in Asano et al. (2018) (Non-Patent Document 6). Specifically, DNA sequences (SEQ ID NO: 4 (DNA sequence encoding SEQ ID NO: 2) and SEQ ID NO: 5 (DNA sequence encoding SEQ ID NO: 3)) encoding the amino acid sequence from amino acids 33 to 252 of human tissue factor (hTF) with a His tag attached to the N-terminus or C-terminus (SEQ ID NO: 2 (His tag attached to the N-terminus) and SEQ ID NO: 3 (His tag attached to the C-terminus)) were ligated to the pROXb3 vector, and the Brevibacillus bacteria were transformed with the DNA sequences. As a result, transformants expressing the protein represented by SEQ ID NO: 2 and transformants expressing the protein represented by SEQ ID NO: 3 were obtained.
[0059] Each of the resulting transformants was cultured in TMN medium or PBN medium at 30°C for 48 hours. Culture was carried out with or without the addition of 0.1 M arginine. After culture, the culture was centrifuged at 18,000 G for 10 minutes, separated into a bacterial cell fraction and a supernatant fraction, and rTF expression was confirmed by SDS-PAGE and Western blotting against the His tag. The results of Western blotting are shown in Figure 1. Ni column affinity purification was performed to purify rTF from 100 mL of culture under conditions in which expression was sufficiently confirmed, and the purity of the purified protein was confirmed by SDS-PAGE. The results of SDS-PAGE are shown in Figure 2.
[0060] 2. Test Results As shown in Figure 1, a main band was observed at approximately 30 kDa under all culture conditions, confirming the expression of the target rTF protein. The expression level of rTF fused to a His tag at the C-terminus was higher than that fused to a His tag at the N-terminus. On the other hand, when compared under conditions with and without Arg addition to the medium, the expression levels were equivalent. Therefore, rTF fused to a His tag at the C-terminus was cultured in PBN medium (without Arg), and the supernatant was obtained and subjected to Ni affinity purification.
[0061] As shown in FIG. 2, TF (ie, rTF fused with a His tag at the C-terminus) with sufficient purity could be purified after Ni column affinity purification.
[0062] Example 2: Confirmation of rTF's ability to activate factor VII and factor X 1. Test Method rTF activity was measured using a Tissue Factor Activity Assay kit (abcam, ab108906) according to the package insert. Furthermore, as a control for rTF protein, Recombinant Tissue Factor Protein (abcam, ab119148), an rTF expressed in Escherichia coli in which a His tag was linked to the N-terminus of the amino acid sequence 33 to 252 of human tissue factor (SEQ ID NO: 1), was used. Liposomes, the phospholipids used in measuring blood coagulation activity, were prepared based on the method described in WO 2003 / 015753.
[0063] The rTF and liposomes were each diluted with the 1x Sample Diluent reagent included in the kit and mixed in equal amounts. 10 μL of the rTF and / or liposome mixture was added to the wells, and 70 μL of a mixture of Human Factor VII and Human Factor X diluted in 1x Assay Diluent was added to the wells, mixed, and incubated at 37°C for 30 minutes. Factor Xa Substrate was then added at 20 μL / well, and the mixture was incubated at 37°C for 35 minutes, after which the absorbance at 405 nm was measured. The absorbance measurement results are shown in Table 1.
[0064]
[0065] 2. Test Results According to Table 1, no change in absorbance was observed in any of the dilution series in wells to which Brevibacillus expression-derived rTF alone was added (represented as "BB-derived rTF alone" in Table 1), wells to which liposomes alone were added (represented as "liposomes alone" in Table 1), or wells to which commercially available E. coli expression-derived rTF and liposomes were added (represented as "E. coli-derived rTF + liposomes" in Table 1).
[0066] In contrast, in the wells to which Brevibacillus expression-derived rTF (BB-derived rTF) and liposomes were added (shown as "BB-derived rTF + liposomes" in Table 1), the absorbance at 405 nm increased in an rTF concentration-dependent manner. Since the experiment was carried out twice for each well, the measured absorbance values for each experiment are also shown in Table 1.
[0067] In the coagulation reaction using this kit, TF first activates factor VII, and then the activated factor VII and TF activate factor X. Since the activated factor X can cleave a specific peptide sequence, it cleaves the substrate, increasing the absorbance at 405 nm and producing color. In other words, the above results indicate that rTF derived from expression in Brevibacillus has the ability to activate factor VII and factor X in a concentration-dependent manner. On the other hand, rTF derived from expression in E. coli does not have this activating ability.
[0068] Example 3 - Preparation of rTF Expressed in CHO Cells 1. Test Method rTF was expressed in CHO cells using the ExpiCHO Expression System Kit (Thermo Fisher, A29133) to prepare rTF. According to the kit's package insert, a DNA sequence (SEQ ID NO: 5) encoding the amino acid sequence from 33 to 252 of hTF with a His tag added to the C-terminus (SEQ ID NO: 3) was ligated to the pcDNA3.1(-) plasmid, and the ligated product was transfected into CHO cells.
[0069] After gene transfer, cell culture supernatant was collected on day 8 and Western blotting was performed using biotin-labeled Tissue Factor Antibody (Fitzgerald, 20R-1401) to confirm rTF expression. The results of Western blotting are shown in Figure 3. After confirming expression, rTF was purified by Ni column affinity purification, and the purity of the protein was confirmed by SDS-PAGE. The results of SDS-PAGE are shown in Figure 4.
[0070] 2. Test Results Figure 3 shows that a main band was observed around 38 kDa, demonstrating that rTF was expressed in the supernatant from CHO cells. Figure 4 shows that a main band was observed around 38 kDa, demonstrating that rTF was purified to a sufficient purity after Ni column affinity purification.
[0071] Example 4 Comparison of the Blood Coagulation Activity of rTF Derived from Brevibacillus Expression and rTF Derived from CHO Expression 1. Test Method The rTF derived from Brevibacillus expression and the rTF derived from CHO expression were each dialyzed against a buffer (containing 12.5 mM Tris-HCl and 25 mM NaCl, pH 7.0). Thereafter, before measurement, the rTF was dialyzed against a buffer (containing 12.5 mM Tris-HCl, 25 mM NaCl, and 15 mM CaCl 2 The liposomes were diluted to 0.1 mg / mL or 1 mg / mL with 10% ethanol (pH 7.0). Immediately before measurement, liposomes were added to a final concentration of 150 μM equivalent to phosphatidylcholine, and the prothrombin (PT) times of 10 human plasma samples were measured using a CP3000 automated blood coagulation analyzer (manufactured by Sekisui Medical Co., Ltd.). The measurement results are shown in Table 2.
[0072] 2. Test Results As shown in Table 2, in most samples, regardless of the rTF concentration, the PT time [s] was shorter for the Brevibacillus expression-derived rTF (represented as "Brevibacillus" in Table 2) than for the CHO expression-derived rTF (represented as "CHO" in Table 2). The PT time is the time required for blood to finally clot due to the enzymatic reaction described in Example 2, and a shorter PT time indicates a faster blood coagulation reaction and stronger blood coagulation activity. Therefore, it was revealed that the Brevibacillus expression-derived rTF has higher blood coagulation activity than the CHO expression-derived rTF.
[0073]
[0074] [Sequence List] The amino acid sequences and nucleic acid sequences disclosed herein are shown in Table 3. The underlined portions of the sequences of SEQ ID NOs: 2 to 5 are sequences corresponding to the His tag (6xH).
[0075]
Claims
1. A blood coagulation test reagent containing recombinant tissue factor produced using gram-positive bacteria.
2. The blood coagulation test reagent according to claim 1, wherein the gram-positive bacteria is at least one type of bacteria selected from the group consisting of bacteria of the genus Brevibacillus, bacteria of the genus Lactobacillus, and bacteria of the genus Bacillus.
3. The blood coagulation test reagent according to claim 1 or 2, wherein the recombinant tissue factor has the ability to activate blood coagulation factor VII.
4. The blood coagulation test reagent according to claim 1 or 2, wherein the recombinant tissue factor is an extracellular domain of tissue factor.
5. The blood coagulation test reagent according to claim 1 or 2, further comprising phospholipids and calcium.
6. A method for producing the blood coagulation test reagent according to claim 1 or 2, comprising the step of producing the recombinant tissue factor using a gram-positive bacterium.
7. A method for producing a recombinant tissue factor, comprising the steps of: introducing a gene encoding a recombinant tissue factor into a gram-positive bacterium; selecting a gram-positive bacterium expressing the recombinant tissue factor; and culturing cells expressing the recombinant tissue factor to express the recombinant tissue factor in a culture medium.
8. The method for producing recombinant tissue factor according to claim 7, wherein the gram-positive bacterium is at least one bacterium selected from the group consisting of bacteria of the genus Brevibacillus, bacteria of the genus Lactobacillus, and bacteria of the genus Bacillus.
9. The method for producing a recombinant tissue factor according to claim 7 or 8, wherein the recombinant tissue factor has the ability to activate blood coagulation factor VII.
10. A method for producing a recombinant tissue factor according to claim 7 or 8, wherein the recombinant tissue factor is the extracellular domain of tissue factor.
11. A recombinant tissue factor produced by the method for producing a recombinant tissue factor according to claim 7 or 8.
Citation Information
Patent Citations
Composite factor measurement reagent
JP1999160320A
Production of functional recombination tissue factor
JP1999225760A
Reagent for coagulation inspection and manufacturing method therefor
JP2008122288A
Blood collection tube, agent and blood character analysis method using the same
JP2021073479A
Peptide tags and tagged proteins containing the same
JP2022044600A
